Dishman Carbogen Amcis Limited has informed the Exchange regarding Outcome of Board Meeting held on March 18, 2026.
DCAL · price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
On the reaction day the stock moved 3.1 pts less than Nifty Microcap 250 and 4.1 pts less than its Pharmaceuticals peers, over the same two closes: a difference in percentage points, not a measure of what the filing did.
Minute windows have no benchmark: there is no intraday index history to compare against.
Dishman Carbogen Amcis has received board approval to raise up to Rs. 150 crores by issuing senior, secured, rated, listed, redeemable Non-Convertible Debentures (NCDs) on a private placement basis. The issuance is split into two tranches: Rs. 100 crores (10,000 NCDs of Rs. 1 lakh each) with an 18-month tenure and bullet repayment at maturity, and Rs. 50 crores (5,000 NCDs with a base issue of Rs. 35 crores plus a Rs. 15 crore green-shoe option) with a 24-month tenure and partial repayments (35% at 18 months, 65% at 24 months). Both tranches carry a coupon of 10% per annum, payable quarterly, and will be secured with 1.1x asset cover including a promoter property guarantee and charges over company assets. The NCDs will be listed on the BSE Wholesale Debt Market segment, with allotments expected around March 27-30, 2026.
For shareholders, this is a debt raise (not equity dilution), so there is no immediate dilution risk, but it adds Rs. 150 crores to the company's debt burden with interest costs of around Rs. 15 crores per year. The 10% coupon is attractive for institutional debt investors, and the secured nature with promoter-backed collateral signals reasonable credit quality. Equity investors should watch for the stated purpose of the funds, which is not detailed in this filing.